Treatment Persistence in Psoriasis Patients Initiated on Apremilast, Oral Systemics, or Biologic Therapies

Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.2397
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pss23 - Switch Patterns and Total Costs in Biologic-Naive Patients Initiating Apremilast or a Biologic for the Treatment of Psoriasis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Health Care Costs in Psoriasis Patients Newly Initiated on a Biologic Therapy or Methotrexate

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Comparison of Persistence Between Adults With Psoriasis Initiating Apremilast or Biologics

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Risk of Cancer in Patients With Psoriasis on Biologic Therapies: A Systematic Review

British Journal of Dermatology
DermatologyMedicine
2017English

Biologic Therapies in HIV-infected Patients With Psoriasis: An Italian Experience

Acta Dermato-Venereologica
DermatologyMedicine
2017English

Persistence Rate With Subcutaneous Biologic Therapies in Patients With Ankylosing Spondylitis (As)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Persistence Rate With Subcutaneous Biologic Therapies in Patients With Rheumatoid Arthritis (Ra)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Utility of Apremilast in the Treatment of Psoriasis

International Journal of Basic & Clinical Pharmacology
2018English

PSS14 Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy